DiaMedica Therapeutics (DMAC) Cash from Financing Activities (2018 - 2026)

DiaMedica Therapeutics has reported Cash from Financing Activities for 9 years, with the latest figure at $417000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 358.24% year-over-year to $417000.0; the trailing twelve-month figure through Mar 2026 stood at $44.2 million (up 265.73% YoY), and the FY2025 full-year result was $43.9 million, up 265.82% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $417000.0, down from $12.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $36.8 million in Q2 2023, with the low at -$6000.0 in Q3 2023.
• Historically, Cash from Financing Activities has averaged $5.5 million across 5 years, with a median of $91000.0 in 2025.
• The largest YoY upside for Cash from Financing Activities was 1842600.0% in 2023 against a maximum downside of 200.0% in 2023.
• DiaMedica Therapeutics' Cash from Financing Activities stood at -$1000.0 in 2022, then changed by 0.0% to -$1000.0 in 2023, then soared by 12100.0% to $120000.0 in 2024, then jumped by 9975.83% to $12.1 million in 2025, then plunged by 96.55% to $417000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $417000.0 (Q1 2026), $12.1 million (Q4 2025), and $31.5 million (Q3 2025), per Business Quant data.